PUNE, India, June 1, 2016 /PRNewswire/ --
The "Type 2 Diabetes - Pipeline Review, H1 2016" is a professional and in-depth market research report providing an overview of therapeutic pipeline for Type 2 diabetes complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Type 2 Diabetes with 358 market data tables and 17 figures, spread across 1329 pages is available at http://www.lifescienceindustryresearch.com/type-2-diabetes-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Type 2 Diabetes Pipeline Review, H1 2016 report include Addex Therapeutics Ltd, Adocia, Advinus Therapeutics Ltd., Aegis Therapeutics, LLC, AFFiRiS AG, Alchemia Limited, Alize Pharma SAS, AlphaMab Co., Ltd, Amarantus Bioscience Holdings, Inc., Ambrx, Inc., Amgen Inc., Anchor Therapeutics, Inc., AntriaBio, Inc., Aphios Corporation, Araim Pharmaceuticals, Inc., Arisaph Pharmaceuticals, Inc., ArisGen SA, Array BioPharma Inc., Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca Plc, AUS Bio Limited, Avaxia Biologics, Inc., Bayer AG, Beta-Cell NV, Betagenon AB, Biocon Limited, Biodel Inc., Biogenomics Limited, BioLingus AG, BioRestorative Therapies, Inc., BioTherapeutics Inc., BioTime, Inc., Biscayne Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Boston Therapeutics, Inc., Braasch Biotech LLC, Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, Cadila Pharmaceuticals Limited, Caldan Therapeutics Limited, Cardax Pharmaceuticals, Inc., Carlina Technologies SAS, Carmot Therapeutics, Inc., Catabasis Pharmaceuticals, Inc., Celon Pharma Sp. z o.o., Chipscreen Biosciences Ltd, Chong Kun Dang Pharmaceutical Corp., CJ HealthCare Corp., CohBar, Inc., Connexios Life Sciences Pvt. Ltd., Corium International, Inc., CSL Limited, CureDM, Inc., CymaBay Therapeutics, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Dance Biopharm Inc., Debiopharm International SA, Delpor, Inc., Diabetica Limited, Diabetology (Products) Ltd, DiaMedica Inc., Diasome Pharmaceuticals, Inc., DiscoveryBiomed, Inc., Eisai Co., Ltd., Elcelyx Therapeutics, Inc., Eli Lilly and Company, enGene, Inc, Enzo Biochem, Inc., Epichem Pty Ltd, Esperion Therapeutics, Inc., Eternygen GmbH, Euroscreen S.A., Evotec AG, F. Hoffmann-La Roche Ltd., FibroStatin SL, Flamel Technologies S.A., Foresee Pharmaceuticals, LLC, Generex Biotechnology Corporation, Genfit SA, Genovate Biotechnology Co., LTD., Gero Corp, Geropharm, GlaxoSmithKline Plc, Glide Pharmaceutical Technologies Limited, Glucox Biotech AB, GW Pharmaceuticals Plc, Hadasit Medical Research Services & Development Ltd, Halozyme Therapeutics, Inc., HanAll Biopharma Co., Ltd., Handok Inc., Hanmi Pharmaceuticals, Co. Ltd., Heptares Therapeutics Limited, Hua Medicine Ltd., Hyundai Pharmaceutical Co., Ltd., Immuron Limited, Innopharmax Inc., Intarcia Therapeutics, Inc., Integral Molecular, Inc., IntelliCell BioSciences Inc., Intercept Pharmaceuticals, Inc., Intrexon Corporation, Ionis Pharmaceuticals, Inc., IPCA Laboratories Limited, Islet Sciences, Inc., iTherX, Inc., Japan Tobacco Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., JHL Biotech, Inc., Jiangsu Hengrui Medicine Co., Ltd., Johnson & Johnson, Kadimastem Ltd., Kadmon Corporation, LLC, Kareus Therapeutics, SA, Kissei Pharmaceutical Co., Ltd., Lexicon Pharmaceuticals, Inc., LG Life Science LTD., Ligand Pharmaceuticals, Inc., Lonestar Heart, Inc., Longevity Biotech, Inc, Magnus Life Science, Medesis Pharma S.A., Medestea Research & Production S.p.A., MedImmune, LLC, Mellitech SAS, Merck & Co., Inc., Mesoblast Limited, Metabolic Solutions Development Company, LLC, Metabolys SAS, MI.TO. Technology S.r.L., MicroBiome Therapeutics LLC, MidaSol Therapeutics LP, Mitsubishi Tanabe Pharma Corporation, Naia Limited, Neurimmune Holding AG, Neurocrine Biosciences, Inc., NGM Biopharmaceuticals, Inc., Nimbus Therapeutics, LLC, NOD Pharmaceuticals, Inc., Nordic Bioscience A/S, Novartis AG, NovaTarg Therapeutics, Inc, Novo Nordisk A/S, Noxxon Pharma AG, Omeros Corporation, OPKO Health, Inc., Oramed Pharmaceuticals, Inc., Orbis Biosciences, Inc., Panacea Biotec Limited, Paras Biopharmaceuticals Finland Oy, Peptron, Inc., Pfizer Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pivot Pharmaceuticals Inc, Poxel SA, Progen Pharmaceuticals Limited, Prometheon Pharma, LLC, ProMetic Life Sciences Inc., Prothena Corporation Plc, Purzer Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Red Glead Discovery AB, RegenMedTX, LLC, reMYND NV, Rhizen Pharmaceuticals S.A., Rhythm Pharmaceuticals, Inc., Saniona AB, Sanofi, Sanwa Kagaku Kenkyusho Co., Ltd., SATT Conectus Alsace SAS, SBI Pharmaceuticals Co., Ltd., Seres Therapeutics, Inc., Serodus ASA, Serometrix, LLC, Sevion Therapeutics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Shanghai Pharmaceutical Co., Ltd., Shantani Proteome Analytics Pvt. Ltd., Shionogi & Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Sirona Biochem Corp, SJT Molecular Research, S.L., SK Chemicals Co., Ltd., Sprint Bioscience AB, Starpharma Holdings Limited, Stelic Institute & Co., Inc., Strongbridge Biopharma plc, Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Theracos, Inc., Therapix Biosciences Ltd, Thermalin Diabetes, LLC, Thetis Pharmaceuticals LLC, Toray Industries, Inc., Torrent Pharmaceuticals Limited, Transgene Biotek Limited, TWi Pharmaceuticals, Inc., Uni-Bio Science Group Ltd., Valeant Pharmaceuticals International, Inc., Vicore Pharma AB, Viking Therapeutics, Inc., Virobay Inc., Vivus, Inc., vTv Therapeutics LLC, Vybion, Inc., XBiotech USA, Inc., Xenetic Biosciences (UK) Limited, Xizang Haisco Pharmaceutical Group Co., Ltd., XL-protein GmbH, XOMA Corporation, Yuhan Corporation, Yungjin Pharm. Co., Ltd., Zafgen Inc., Zealand Pharma A/S, Zensun (Shanghai) Sci & Tech Co., Ltd. and Zydus Cadila Healthcare Limited.
Order a copy of Type 2 Diabetes - Pipeline Review, H1 2016 market research report @ http://www.lifescienceindustryresearch.com/purchase?rname=113854 .
Explore more reports on Pharmaceuticals.
About Us:
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@lifescienceindustryresearch.com
Connect with Us:
G+ / Google Plus: https://plus.google.com/112612135957880308475/about
Twitter: https://twitter.com/LifeSciReports
RSS / Feeds: http://www.lifescienceindustryresearch.com/feed
